Seres Therapeutics (MCRB) EBT (2014 - 2026)

Seres Therapeutics has disclosed EBT across 13 years of filings, most recently posting -$21.1 million for Q2 2026.

• In Q2 2026, EBT rose 13.33% year-over-year to -$21.1 million; the TTM figure through Jun 2026 stood at -$82.5 million (up 23.55% YoY), while the FY2025 annual figure was -$91.7 million, up 21.82% from the prior year.
• EBT came in at -$21.1 million for Q2 2026 at Seres Therapeutics, down from -$20.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of $48.1 million in Q2 2023 to a low of -$71.5 million in Q1 2023.
• Average EBT over 5 years is -$29.7 million, with a median of -$28.0 million recorded in 2024.
• The largest YoY upside for EBT was 174.6% in 2023 against a maximum downside of 1495.49% in 2023.
• Over 5 years, EBT stood at -$2.2 million in 2022, then tumbled by 1495.49% to -$35.1 million in 2023, then climbed by 18.99% to -$28.4 million in 2024, then surged by 33.33% to -$18.9 million in 2025, then declined by 11.41% to -$21.1 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$21.1 million in Q2 2026, -$20.6 million in Q1 2026, and -$18.9 million in Q4 2025.